The latest call
FetchingEmergent Biosolutions Inc. reported on November 2, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
EBS · NYSE · Healthcare · Drug Manufacturers Specialty and Generic
$5.79-1.7%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 3, 2026
Company outlook: revenue of $600M to $645M for Fiscal year 2026 — down 16.2% on a year earlier ($742.9M)
Just reported
From Emergent Biosolutions Inc.'s results release of November 2, 2026; its quarterly report has since been filed.
Actual
$110M
-52% y/y
-53% q/q
Guided
$120M
midpoint
Actual
-$0.64
Guided
—
No guide given
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $110M | $231.1M | -52.40% |
| Profit | -$32.7M | $51.2M | -163.87% |
| Profit per share | -$0.64 | $0.91 | -170.33% |
| Free Cash Flow | $96.8M | -$5.7M | +1,798.25% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Emergent Biosolutions Inc. reported on November 2, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Emergent's third-quarter results, which include revenue of $110.0 million inline with our guidance, were primarily driven by our diverse biodefense/medical countermeasures and naloxone portfolio, underscoring the importance of disciplined execution as we advance our multi-year transformation,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
The quote and the company description come from Emergent Biosolutions Inc.’s Item 2.02 8-K filed November 2, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Actual
-$37.3M
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.